PharmaCyte Biotech, Inc.
PMCB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001157075
No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding PharmaCyte Biotech, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 25 | 1 | 30 | +6 |
| Shares | 433.4K | 50 | 984.1K | +550.8K (+127.1%) |
| Value | $419.9K | $1 | $712.0K | +$292.1K (+69.6%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 182,801 | $132.0K | 0.00% |
| Sabby Management, LLC | 100,000 | $72.4K | 0.60% |
| Two Sigma Securities, LLC | 24,553 | $17.8K | 0.00% |
| XTX Topco Ltd | 24,442 | $17.7K | 0.00% |
| Jane Street Group, LLC | 11,391 | $8.25K | 0.00% |
| Aviso Financial Inc. | 12 | $8 | 0.00% |
| MCF Advisors LLC | 1 | $1 | 0.00% |
Sold out (1)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Citigroup Inc | 1 | $1 |
Not filed for Q4 2025 yet (1)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Accredited Wealth Management, LLC | 50 | $1 |